Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting

ConditionPsychosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPakistan Institute of Living and Learning

About this trial

Primary Aims:

To determine the clinical efficacy of Culturally adapted Cognitive Behavioral Therapy (CaCBT) and Culturally adapted Family Intervention (CulFI) compared to Treatment As Usual (TAU) on reducing overall symptoms of psychosis in patients with First Episode Psychosis (FEP) in Pakistan.

Secondary Aims:

1. To determine the efficacy of CaCBT and CulFI compared to TAU on positive and negative symptoms of psychosis, general psychopathology, depressive symptoms, quality of life, general functioning, and insight in patients with FEP in Pakistan. 2. To determine the efficacy of CaCBT and CulFI compared to TAU on improving carer experience, carer wellbeing, carer illness attitudes and symptoms of depression and anxiety in family and carers of patients with FEP in Pakistan. 3. To determine the comparative effect of CaCBT and CulFI in improving patient and carer related outcomes in individuals with FEP in Pakistan. 4. To estimate the economic impact of delivering culturally appropriate psychosocial interventions in low-resource settings 5. To explore delivery and reach of each intervention, tolerability of intervention components, acceptability of interventions, understanding mechanism of change and developing an understanding of barriers and facilitators to future adoption using process evaluation.

Study design and setting:

This will be a multi-centre, assessor masked, individual, three-arm randomised controlled trial (RCT).

Sample Size:

The study aims to recruit a total of N=390 participants with FEP

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Individuals of all genders aged over 18 years; diagnosis of schizophrenia confirmed by Structured Clinical Interview for DSM (SCID) meeting DSM-5 criteria for schizophrenia, schizophreniform or schizoaffective psychosis

Scored at least 4 on the PANSS delusions or hallucinations items, or at least 5 on suspiciousness, persecution, or grandiosity items

stable on medication for the past four weeks

in contact with mental health services

Disqualifiers

Active DSM-5 substance use disorder (except nicotine or caffeine) or dependence within the last three months

A score of 5 or more on the PANSS conceptual disorganisation item

Individuals who have received structured psychological intervention within the past 3 months

Relevant CNS or other medical disorders that would impact participation

Trial design

Design model

Parallel

Treatments tested in this trial

  • CaCBT for psychosis

    Behavioral

    The CaCBT intervention is based on the intervention manual developed by David Kingdon and Douglas Turkington, and culturally adapted by our group. CaCBT aims to take a collaborative approach to gaining an understanding of the symptoms

  • Culturally adapted Family Intervention (CulFI) for psychosis

    Behavioral

    CulFI intervention comprises of Family psychoeducation; cognitive-behavioural skills training for stress-management, coping and problem solving; crisis intervention and suicide risk management; relapse prevention; education and support regarding the family environment, including communication training. The components are designed to facilitate an understanding about psychosis, the emotional impact of the illness on family relationships, to promote more adaptive coping strategies and minimize relapse risk.

Treatment groups

390 Participants
are divided into 3 treatment groups
Group A: CaCBT for psychosisExperimental treatment 1 intervention
Group B: CulFI InterventionExperimental treatment 1 intervention
Group C: Treatment as Usual (TAU)No intervention 0 interventions

Trial outcomes

Primary outcomes

1

Positive and Negative Syndrome Scale

The PANSS is a structured interview use to evaluate the prevalence and severity of the positive, negative and general psychiatric symptoms of schizophrenia. The higher the score the greater symptoms severity. potential ranges are 7 to 49 for the Positive and Negative Scales, and 16 to 112 for the General Psychopathology Scale.

Time frame
Change in scores from baseline to months 3, 6, and 12

Secondary outcomes

1

Calgary Depression Scale for Schizophrenia

The CDSS is a 9-items scale which evaluates depression in individuals with psychosis. The minimum score is 0 and maximum 30.Higher scores indicate greater depressive severity

Time frame
Change in scores from baseline to months 3, 6, and 12
2

EuroQol-5 Dimensions

EuroQol-5D (EQ- 5D) will be used to assess health-related quality of life over 5 dimensions (mobility, self-care, daily activities, pain-discomfort, anxiety and depression). Higher score indicates better quality of life.

Time frame
Change in scores from baseline to months 3, 6, and 12
3

World Health Organization Disability Assessment Scale

It is a self-administered questionnaire based on 36 items that measures health and disability. The scoring has three steps: Step 1 - Summing of recoded item scores within each domain. Step 2 - Summing of all six domain scores. Step 3 - Converting the summary score into a metric ranging from 0 to 100 (where 0 = no disability; 100 = full disability

Time frame
Change in scores from baseline to months 3, 6, and 12
4

Schedule for Assessment of Insight

The Schedule for Assessment of Insight is used to evaluate the three different aspects of insight: treatment compliance, recognition of illness and re-labelling of psychotic phenomena

Time frame
Change in scores from baseline to months 3, 6, and 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Pakistan Institute of Living and Learning

Lead sponsor

Centre for Addiction and Mental Health

Collaborator